

DR ALLAN GAW - LECTURING

I have been lecturing in the UK and throughout the world for the last 18 years. The majority of my lecturing has been to post-graduate medical audiences (GPs, Internists, Cardiologists, Cardiac Surgeons, Clinical Biochemists, and Lipidologists) in this country, Europe, Asia, Australia and South America. I have also lectured to undergraduate medical, nursing and science students as well as on Masters level Nursing and Clinical Pharmacology courses.

Since 2003, I also delivered a range of postgraduate workshops on topics related to the conduct of clinical trials including a one day workshop on Good Clinical Practice.

My range of over 100 invited lectures to Hospital and University Departments and conferences is listed below

INVITED PRESENTATIONS

1. *The Arts: What can Literature and the Arts Contribute to the Teaching of Bioethics?* Ethics, Law and Communication Skills An International Symposium on Health Care Education, Oxford, April 10, 1991.
2. *Rationale for Secondary Prevention.* SHARP Nurses Study Day, Lancaster House Postgraduate Centre, Glasgow, November 19, 1994.
3. *The Growing Evidence for Treatment.* SHARP Meeting, A New Consensus in Coronary Heart Disease and Cholesterol, Glasgow March 22, 1995.
4. *Secondary Prevention: Lifestyle Changes.* 12th Annual Practice Nurse Convention, Edinburgh, April 6, 1995.
5. *LDL Subfractions: An Atherogenic Role.* Russian Academy of Medicine meeting: Man and Medicine. Satellite Symposium: Management of Lipid Disorders, Moscow, Russia, April 11, 1995.
6. *Lipoprotein (a): Molecular Genetics and Measurement.* Association of Clinical Biochemists Scottish Regional Meeting, Edinburgh, June 14, 1995.
7. *Genetics of Lipoprotein (a).* British Hyperlipidaemia Association Annual Meeting, Birmingham, July 6, 1995.
8. *Secondary Prevention of Coronary Heart Disease in Practice.* Update in Cardiology I, Lancaster House Postgraduate Centre, Glasgow Sept 13, 1995.
9. *Lp(a): Molecular Genetics and Cardiovascular Risk.* XIIIth Congress of the Polish Society of Laboratory Diagnostics, Warsaw, Poland, Sept 23, 1995.
10. *Lipid Risk Factors for Stroke.* 3rd International Conference on Stroke, Prague, Czech Republic, October 20, 1995.
11. *New evidence for lipid lowering: the West of Scotland Coronary Prevention Study.* Irish Hyperlipidaemia Association, Belfast, December 2, 1995.
12. *Primary and secondary prevention workshops.* SHARP Winter Scientific Meeting, Dunkeld, December 8, 1995.

13. *Pharmacology of the HMG CoA reductase inhibitors.* International Society of Cardiovascular Pharmacotherapy, Sydney, February 25, 1996.
14. *Lipoprotein (a): Molecular Genetics and Metabolism.* Swedish Heart Association Meeting, Lejonadal Slott, Stockholm, Sweden, March 17, 1996.
15. *Human Lipoprotein Metabolism.* Institute of Food Research, Norwich, March 19, 1996.
16. *Clinical Implications of WOSCOPS.* The Pentagon Group, Tiverton, March 22, 1996.
17. *Plaque Regression and Stabilisation.* Atheroma Regression Therapy (ART) III. Portsmouth, May 14, 1996.
18. *The West of Scotland Coronary Prevention Study.* Prevencion Primaria Y Secundaria Perspectivas Para El Año 2000, Cartagena, Colombia, May 27, 1996.
19. *Interpreting Clinical Trials with Examples of Good and Bad Design.* ACB National Training Course, Glasgow, September 19, 1996.
20. *Hyperlipidaemia and Hypertension in the Elderly. Is there need for special care?* 3rd Congress of the International Association of Gerontology, European Region - Clinical Session, Thessaloniki, Greece, November 16, 1996.
21. *The diagnosis and management of mixed hyperlipidaemia* SHARP Winter Scientific Meeting, Dunkeld, November 28, 1996.
22. *Statins - new evidence for coronary prevention.* Grand Round. Leeds General Infirmary, Leeds, January 8, 1997.
23. *WOSS and CARE - Putting the evidence into practice.* Southwestern Fundholders Annual Conference, Torquay, March 13, 1997.
24. *Cholesterol - how low and why?* The Pentagon Group, Tiverton, March 14, 1997.
25. *Lipoprotein (a) - research update.* Glasgow Royal Infirmary Grand Round, Glasgow, March 26, 1997.
26. *Evidence based approach for the management of mixed hyperlipidaemia.* Plenary Session European Atherosclerosis Society Annual Meeting Brugge, Belgium, May 9, 1997.
27. *Event reduction in patients with elevated cholesterol and no documented coronary heart disease: WOSCOP Trial.* CardioSphere Satellite Meeting, Montreal, Canada, June 30, 1997.
28. *Preventing clinical events in patients at risk.* International Conference on Preventive Cardiology, Montreal, Canada, June 30, 1997.
29. *Percentage cholesterol reduction versus risk reduction.* European Society of Cardiology Annual Meeting, Stockholm, Sweden, August 25, 1997.

30. *Cholesterol therapy in healthy patients.* XVI Interamerican Congress of Cardiology, Fajardo, Puerto Rico September 15, 1997.
31. *Effects of ciprofibrate on the LDL subfraction profile.* I. Symposium o ateroskleroze a dyslipoproteinemiach. Bratislava, Slovakia, October 14, 1997.
32. *Lipid lowering drugs.* 3rd Year Biomedical Science course. University of Durham, October 28, 1997.
33. *Development of lipid guidelines.* Clinical Biochemistry Dept., Royal Infirmary, Edinburgh January 23, 1998.
34. *PROSPER: Prospective Study of Pravastatin in the Elderly at Risk.* Plenary Lecture at the International Congress of Vascular Disease Prevention, Glasgow May 8, 1998.
35. *Currently postulated mechanisms for the clinical effectiveness of HMG Co A reductase inhibitors.* XVI World Congress of the International Society for Heart Research, Rhodes, Greece May 30, 1998.
36. *Lipid lowering drugs.* BHA Healthcare Section Plenary Lecture, Glasgow July 3, 1998.
37. *New Roads in the Prevention of Cardiovascular Disease.* World Congress of Internal Medicine, Lima, Peru, November 4, 1998.
38. *New Insights into the control of plasma Lp(a).* Biochemical Society 668th Meeting, Glasgow, April 1999.
39. *The metabolic basis of the lipid hypothesis.* Association of Clinical Biochemists, Glasgow, May 1999.
40. *Epidemiology and Pathophysiology of Coronary Heart Disease and Lipids, Statins and Coronary Disease Prevention.* Rehabilitation in Cardiology MSc Course Caledonian University, Glasgow, February 2000.
41. *Statins in acute coronary syndromes* International Society of Atherosclerosis, Stockholm, Sweden, June 2000.
42. *Outcome Trials and Evidence Based Medicine* European Society of Cardiology Masterclass, Cork, Ireland, June 2000.
43. *All statins are not the same – debate.* European Society of Cardiology Amsterdam, The Netherlands, 2000.
44. *How do clinical trials affect policy development?* Future Forum Conference, London, 2001.
45. *Statins and Plaque Control* 5th UK Renovascular Forum, Royal College of Physicians and Surgeons, Glasgow March 2001.
46. *Healthy ageing: addressing acute coronary syndrome?* European Atherosclerosis Society, Glasgow May 2001.

47. *All statins are the same? – a debate.* European Cardiology Society, Stockholm, Sweden, September, 2001.
48. *Preventing vascular disease in the elderly.* Royal Alexandra Hospital Grand Rounds, Paisley, April 2002.
49. *Cardiovascular disease prevention in the elderly: the role of statins.* British Geriatric Society, June Belfast June 2002.
50. *Statin therapy in clinical practice: an evidence based approach.* Thailand Cardiology Society, Phuket, Thailand, August 2002.
51. *Primary prevention in clinical practice.* Eicosanoids Conference, Taiwan, Taiwan, August 2002.
52. *Meeting CHD Goals – Implications for the Older Patient with cardiovascular Disease.* British Geriatric Society, Cardiology Section, Birmingham, November 2002.
53. *The PROSPER Study.* Bolton Royal Infirmary Grand Rounds, November 2002.
54. *Cardiovascular Disease Prevention in the Elderly,* Royal Liverpool Hospital Grand Rounds, November 2002.
55. *Cardiovascular Disease Prevention in High Risk Groups* Österreichischen Diabetestagung (Austrian Diabetes Society), Graz, Austria, November 2002.
56. *Molecular Genetics of Lipid Disorders* University Hospital Taipei, Taiwan, December 2002.
57. *Prevention of Type 2 Diabetes: Impact of Pravastatin in the West of Scotland Coronary Prevention Study.* Taiwanese Diabetes Society Meeting, Taipei, Taiwan, December 2002.
58. *PROSPER Study – Main Results.* Clinical Trials Services Unit SEARCH and PROCARDIS Investigators Meeting, Oxford, April 2003.
59. *Statin Therapy in the Elderly.* Pan-Yorkshire Cardiology Forum, Leeds April 2003.
60. *Statins and Cardiovascular Disease Prevention.* Satellite meeting of the British Cardiac Society Meeting, Glasgow, April 2003.
61. *The PROSPER Study Plenary session - Focus 2003,* National Meeting of the Association of Clinical Biochemists, Manchester, May 2003.
62. *Meeting cholesterol targets* Southern General Hospital Grand Rounds, Glasgow, June 2003.
63. *The Future of Clinical Trials,* Hot Topics Meeting, Amsterdam, The Netherlands, June 2003.
64. *Niemann-Pick C1-like-1 Protein: the discovery of the cholesterol transporter.* National Ezetimibe Advisory Board meeting, Birmingham, March, 2004.

65. *Statin therapy: simple and effective.* Statin Therapy, Shaping the Future. Rio de Janeiro, Brazil, March 2004.
66. *Statin therapy in modern clinical practice.* Onassio Lipid Symposium, Athens, Greece June, 2004.
67. *Rosuvastatin- global safety update.* Brazilian Atherosclerosis Society Meeting, Florianopolis, Brazil, August 2004.
68. *Achieving cholesterol targets – new therapeutic options.* 59th Congress of the Brazilian Society of Cardiology, Rio de Janeiro, Brazil September 2004.
69. *Cardiovascular disease: risk factors in perspective.* British HIV Association, 10th Annual Meeting, London, October 2004.
70. *Guidelines Versus Clinical Practice: What Really Works,* XVth International Symposium on Drugs Affecting Lipid Metabolism (DALM), Venice, Italy October 2004.
71. *Challenging CHD in the UK,* Postgraduate Medical Meeting, Stornaway, May 2005.
72. *Challenging CHD in the UK,* Northern General Hospital, Sheffield, Grand Rounds, May 2005.
73. *Challenging CHD in the UK,* Oldchurch Hospital, Romford, Grand Rounds, June 2005.
74. *Challenging CHD in the UK,* Dr Gray's Hospital Elgin, Postgraduate Centre Meeting, June 2005.
75. *Challenging CHD in the UK,* Bradford Royal Infirmary, Lunchtime General Medical Meeting, June 2005.
76. *Molecular Basis of Clinical Lipid Management,* Hairmyres Hospital, East Kilbride, Grand Rounds, June 2005.
77. *Challenging CHD in the UK,* Airedale General Hospital, Postgraduate lunchtime meeting, August 2005
78. *Future of Lipid Management,* Pinderfields Hospital, Cardiology Department Update Meeting, August 2005
79. *Challenging CHD in the UK,* Dewsbury General Hospital, Grand Rounds, August 2005.
80. *Challenging CHD in the UK,* Hartlepool and South Tees Hospital, Post-graduate Medical Seminar, Nov 2005.
81. *Molecular Basis of Clinical Lipid Management,* Crosshouse Hospital, Kilmarnock, Postgraduate Multi-disciplinary Meeting, Nov 2005.
82. *Trial by fire: the history of clinical trials.* Hairmyres Hospital East Kilbride, Grand Rounds, March 2006.

83. *Molecular targets for lipid regulating drugs.* Scottish Society of Anaesthetists Annual Scientific Meeting, November 2006.
84. *Lower Cholesterol Targets.* Hope Hospital Manchester, February 2007
85. *Challenging CHD in the UK.* Furness General Hospital Postgraduate Medical meeting, February 2007.
86. *Comparative Pharmacology of the Statins.* Primary Care Cardiovascular Symposium, Sydney, Australia, March 2007.
87. *Lower cholesterol targets –are your 4 it?* Stirling Royal Infirmary Grand Rounds, March 2007.
88. *Getting to goal and effectively reducing CV risk.* Asean Congress of Cardiology Bali, Indonesia, April 2007.
89. *The Patient with Dyslipidaemia - Comprehensive Management Strategies.* Chinese University of Hong Kong CV Summit, Hong Kong, China, April 2007.
90. *New cholesterol targets.* Wythenshawe Hospital, Manchester, Grand Rounds, October 2007.
91. *New cholesterol targets.* Manchester Royal Infirmary, Postgraduate Centre, November 2007.
92. *HDL Cholesterol Management in Practice, Crosshouse Hospital Kilmarnock, Post Graduate Meeting, December 2007.*
93. *Good cholesterol guide – beyond LDL-C lowering.* Manchester Royal Infirmary, Grand Rounds, January, 2008.
94. *HDL cholesterol management.* Royal Alexandra Hospital, Paisley, Post graduate Meeting, February, 2008
95. *The Glasgow Clinical Research Facility,* Western Infirmary Grand Rounds, February, 2008
96. *Lower cholesterol targets in practice,* Vale of Leven Hospital Post graduate meeting, March, 2008.
97. *Managing triglycerides: what you need to know,* Western General Hospital (HIV Group Meeting), Edinburgh, May 2008.
98. *Lower cholesterol targets: are you for it?* Regional Primary Care Conference, Bristol, June, 2008.
99. *Triglyceride management.* HIV management conference. James Cook Hospital, Middlesborough, November, 2008
100. *Lipids in the very elderly,* British Geriatric Society Cardiovascular Section 3rd Annual SpR Meeting, London, January, 2009.
101. *Triglyceride management.* Infectious diseases Department, North Manchester General Hospital, Post Graduate Meeting, Manchester, February, 2009.

102. *Molecular targets in clinical lipid management.* Ninewells Hospital Cardiology Department Post Graduate Meeting, Dundee, April 2009.
103. *The importance of LDL-cholesterol in managing cardiovascular risk.* Pri-Med Update, Edinburgh, April, 2009.
104. *LDL-cholesterol: intensive therapy, why and how?* Royal Society of Medicine, London, May, 2009.